What Happened
Hepatology specialists at a major university medical center have published the first formal selection framework for choosing between the two medicines now FDA-approved for metabolic dysfunction-associated steatohepatitis (MASH). The clinical review, appearing in October 2026 in the peer-reviewed journal Digestive Diseases and Sciences, includes a treatment algorithm for adults with MASH and moderate-to-advanced fibrosis (stages F2-F3).
The two drugs approach the same disease from different directions. Resmetirom, approved in 2024, is a once-daily oral therapy that targets thyroid hormone receptors in the liver; it reduces liver fat and helps prevent further scarring, and can improve cholesterol — but it does not produce weight loss. Semaglutide, a GLP-1 receptor agonist approved for MASH in 2025, works across the whole body: it drives weight loss, lowers blood sugar, and helps keep fat from accumulating in the liver. It is available as a daily tablet or a weekly injection.
Both medicines succeeded in phase 3 trials, but they have never been tested head-to-head — the gap the new algorithm is designed to bridge at the bedside.
Who Is Affected
- The milder precursor condition, MASLD, now affects roughly one in three people worldwide and about 100 million adults in the United States
- Around one in five MASLD patients progresses to MASH, which raises the risk of cirrhosis, liver failure, liver cancer, and the need for a transplant
- People with obesity, type 2 diabetes, insulin resistance, or high cholesterol carry the highest risk
- Many patients have normal liver enzymes, so standard blood panels alone cannot rule the disease in or out
Timeline
- 2024 — FDA approves resmetirom as the first MASH therapy
- 2025 — FDA approves semaglutide for MASH with moderate-to-advanced fibrosis
- October 2026 — the selection algorithm review is published
- On treatment — follow-up is advised within one to two months of starting, with at least four to six months needed to judge whether fibrosis is improving
What This Means for Researchers
The arrival of two approved therapies ends a long period in which MASH had no approved pharmacological treatment at all — management was limited to weight-loss counseling, bariatric surgery referral, and off-label use of vitamin E or the diabetes drug pioglitazone. The review highlights several research-relevant points:
- Selection is driven by the patient's whole cardiometabolic profile — diabetes, heart disease, cholesterol, gastrointestinal symptoms — not by liver chemistry alone
- Fibrosis staging with noninvasive imaging (FibroScan, MRI elastography) is the entry point for therapy decisions
- Non-responders to one agent may be candidates for switching or combination approaches
- Head-to-head comparative data between the two drugs remains an open question
- Reported side effects — nausea, vomiting, diarrhea — are described as predictable, manageable, and often temporary
- Cost remains a barrier: out-of-pocket expenses can run from hundreds to thousands of dollars per month
How to Verify Your Peptides
For researchers sourcing GLP-1 analogs or related compounds from the gray market, batch quality varies enormously. Independent analytical testing is the only reliable safeguard. PepsReview maintains a testing resource hub at https://pepsreview.com/testing/ covering mass spectrometry, HPLC purity analysis, and at-home verification kits.
Safe Alternatives
Researchers and patients should work only with regulated channels. Information on approved compounds is available at https://pepsreview.com/peptides/, and PepsReview's audited vendor directory — covering purity documentation, third-party testing, and shipping reliability — is at https://pepsreview.com/vendors/.
Sources
Peer-reviewed clinical literature (Digestive Diseases and Sciences, October 2026); regulatory announcements from the U.S. Food and Drug Administration.